Date: 2019-05-20
Type of information: Nomination
Compound: head of R&D
Company: Voyager Therapeutics (USA-MA)
Therapeutic area: Neurological diseases - Neurodegenerative diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On May 20, 2019, Voyager Therapeutics announced the retirement of Dinah Sah, as Voyager’s chief scientific officer, and the appointment by Voyager of Omar Khwaja, currently Voyager’s chief medical officer, to the expanded role of chief medical officer and head of research and development. Both changes will be effective June 28, 2019. Dr. Sah has agreed to serve as a consultant to Voyager and become a member of its scientific advisory board.
- Dr. Khwaja’s background includes extensive research, discovery, translational, and clinical therapeutic development experience in neuroscience, neurogenetics and rare disease in both industry and academic roles. Dr. Khwaja joined Voyager from Roche where he most recently served as global head of neuroscience translational medicine and global head of rare diseases. Before joining Roche, Dr. Khwaja was director of the clinical neurogenetics program at Boston Children’s Hospital and on the faculty of Harvard Medical School. Dr. Khwaja received his M.D. and Ph.D. from the University of Cambridge, Cambridge, UK. He trained in pediatrics and clinical genetics in London, UK and Melbourne, Australia and completed his neurology training at Massachusetts General Hospital and Boston Children’s Hospital, where he was chief resident. He is a member of the Royal Colleges of Physicians of the United Kingdom and a member of the Royal College of Pediatrics and Child Health.
Financial terms:
Latest news:
Is general: Yes
